Candida vaginitis: Virulence, host response and vaccine prospects

Flavia De Bernardis, Sofia Graziani, Flavio Tirelli, Stavroula Antonopoulou

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Vulvovaginal candidiasis is a common mucosal infection affecting a large proportion of women with some of them affected by recurrent often intractable forms of the disease. Thus, there is an increasing interest in understanding the pathogenesis of this disease. The aim of our work was to characterize, in animal models of vaginal candidiasis, the components of the host-fungus interaction at the mucosal level. The evidence of an immune response in the vaginal compartment was very encouraging to identify the proper targets for new strategies for vaccination or immunotherapy of vaginal candidiasis. Aspartyl-proteinase (Sap2), which is an important immunodominant antigens and virulence factors of C.albicans acting in mucosal infections, was assembled with virosomes and a vaccine PEV7 was obtained. The results obtained in the mouse model and in the clinical trial conducted by Pevion on women have evidenced that the vaccine PEV7, intravaginally administered, has an encouraging therapeutic potential for the treatment of recurrent vulvovaginal candidiasis. This opens the way to a modality for anti-Candida protection at mucosal level.

Original languageEnglish
Pages (from-to)S26-S31
JournalMedical Mycology
Volume56
DOIs
Publication statusPublished - Apr 1 2018
Externally publishedYes

Fingerprint

Vulvovaginal Candidiasis
Vaginitis
Candidiasis
Candida
Virosome Vaccines
Virulence
Vaccines
Aspartic Acid Proteases
Immunodominant Epitopes
Virulence Factors
Infection
Immunotherapy
Vaccination
Fungi
Animal Models
Clinical Trials
Therapeutics

Keywords

  • aspartyl-proteinase
  • Candida vaginitis
  • immune-response
  • mucosal anti- Candida vaccine
  • virulence factors

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

De Bernardis, F., Graziani, S., Tirelli, F., & Antonopoulou, S. (2018). Candida vaginitis: Virulence, host response and vaccine prospects. Medical Mycology, 56, S26-S31. https://doi.org/10.1093/mmy/myx139

Candida vaginitis : Virulence, host response and vaccine prospects. / De Bernardis, Flavia; Graziani, Sofia; Tirelli, Flavio; Antonopoulou, Stavroula.

In: Medical Mycology, Vol. 56, 01.04.2018, p. S26-S31.

Research output: Contribution to journalReview article

De Bernardis, F, Graziani, S, Tirelli, F & Antonopoulou, S 2018, 'Candida vaginitis: Virulence, host response and vaccine prospects', Medical Mycology, vol. 56, pp. S26-S31. https://doi.org/10.1093/mmy/myx139
De Bernardis F, Graziani S, Tirelli F, Antonopoulou S. Candida vaginitis: Virulence, host response and vaccine prospects. Medical Mycology. 2018 Apr 1;56:S26-S31. https://doi.org/10.1093/mmy/myx139
De Bernardis, Flavia ; Graziani, Sofia ; Tirelli, Flavio ; Antonopoulou, Stavroula. / Candida vaginitis : Virulence, host response and vaccine prospects. In: Medical Mycology. 2018 ; Vol. 56. pp. S26-S31.
@article{c5882b23dd1e43a38cad7aef1374f385,
title = "Candida vaginitis: Virulence, host response and vaccine prospects",
abstract = "Vulvovaginal candidiasis is a common mucosal infection affecting a large proportion of women with some of them affected by recurrent often intractable forms of the disease. Thus, there is an increasing interest in understanding the pathogenesis of this disease. The aim of our work was to characterize, in animal models of vaginal candidiasis, the components of the host-fungus interaction at the mucosal level. The evidence of an immune response in the vaginal compartment was very encouraging to identify the proper targets for new strategies for vaccination or immunotherapy of vaginal candidiasis. Aspartyl-proteinase (Sap2), which is an important immunodominant antigens and virulence factors of C.albicans acting in mucosal infections, was assembled with virosomes and a vaccine PEV7 was obtained. The results obtained in the mouse model and in the clinical trial conducted by Pevion on women have evidenced that the vaccine PEV7, intravaginally administered, has an encouraging therapeutic potential for the treatment of recurrent vulvovaginal candidiasis. This opens the way to a modality for anti-Candida protection at mucosal level.",
keywords = "aspartyl-proteinase, Candida vaginitis, immune-response, mucosal anti- Candida vaccine, virulence factors",
author = "{De Bernardis}, Flavia and Sofia Graziani and Flavio Tirelli and Stavroula Antonopoulou",
year = "2018",
month = "4",
day = "1",
doi = "10.1093/mmy/myx139",
language = "English",
volume = "56",
pages = "S26--S31",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Candida vaginitis

T2 - Virulence, host response and vaccine prospects

AU - De Bernardis, Flavia

AU - Graziani, Sofia

AU - Tirelli, Flavio

AU - Antonopoulou, Stavroula

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Vulvovaginal candidiasis is a common mucosal infection affecting a large proportion of women with some of them affected by recurrent often intractable forms of the disease. Thus, there is an increasing interest in understanding the pathogenesis of this disease. The aim of our work was to characterize, in animal models of vaginal candidiasis, the components of the host-fungus interaction at the mucosal level. The evidence of an immune response in the vaginal compartment was very encouraging to identify the proper targets for new strategies for vaccination or immunotherapy of vaginal candidiasis. Aspartyl-proteinase (Sap2), which is an important immunodominant antigens and virulence factors of C.albicans acting in mucosal infections, was assembled with virosomes and a vaccine PEV7 was obtained. The results obtained in the mouse model and in the clinical trial conducted by Pevion on women have evidenced that the vaccine PEV7, intravaginally administered, has an encouraging therapeutic potential for the treatment of recurrent vulvovaginal candidiasis. This opens the way to a modality for anti-Candida protection at mucosal level.

AB - Vulvovaginal candidiasis is a common mucosal infection affecting a large proportion of women with some of them affected by recurrent often intractable forms of the disease. Thus, there is an increasing interest in understanding the pathogenesis of this disease. The aim of our work was to characterize, in animal models of vaginal candidiasis, the components of the host-fungus interaction at the mucosal level. The evidence of an immune response in the vaginal compartment was very encouraging to identify the proper targets for new strategies for vaccination or immunotherapy of vaginal candidiasis. Aspartyl-proteinase (Sap2), which is an important immunodominant antigens and virulence factors of C.albicans acting in mucosal infections, was assembled with virosomes and a vaccine PEV7 was obtained. The results obtained in the mouse model and in the clinical trial conducted by Pevion on women have evidenced that the vaccine PEV7, intravaginally administered, has an encouraging therapeutic potential for the treatment of recurrent vulvovaginal candidiasis. This opens the way to a modality for anti-Candida protection at mucosal level.

KW - aspartyl-proteinase

KW - Candida vaginitis

KW - immune-response

KW - mucosal anti- Candida vaccine

KW - virulence factors

UR - http://www.scopus.com/inward/record.url?scp=85044753802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044753802&partnerID=8YFLogxK

U2 - 10.1093/mmy/myx139

DO - 10.1093/mmy/myx139

M3 - Review article

C2 - 29538739

AN - SCOPUS:85044753802

VL - 56

SP - S26-S31

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

ER -